Fungal Pneumonia-Introduction, Common fungi, Clinical Feature, Lab Diagnosis, Treatment, and Prevention

Introduction

Fungal pneumonia or invasive fungal pulmonary infection is often life-threatening, especially in immunocompromised patients, such as those with cancer, undergoing chemotherapy, or with HIV/AIDS. pulmonary inflammation caused by inhaled fungal spores or hematogenous fungal spread, leading to pneumonia-like illness.

Common Fungi Causing Pulmonary Infections:

Fungal Pathogen	Key Features	Common in
Aspergillus spp.	Acute angle branching septate hyphae	Cancer, transplant, ICU
Cryptococcus neoformans/gattii	Encapsulated yeast	HIV/AIDS, malignancy
Pneumocystis jirovecii	Non-cultivable, alveolar foamy exudate	AIDS (CD4 <200)
Histoplasma capsulatum	Intracellular yeast (in macrophages)	Endemic areas (e.g., India, USA)
Blastomyces dermatitidis	Broad-based budding yeast	Rare, endemic
Coccidioides spp.	Spherules with endospores	Desert regions (e.g., Arizona, Africa)
Mucorales (e.g., Rhizopus)	Broad aseptate hyphae	Diabetic ketoacidosis, cancer

Clinical Features

• Fever, cough, hemoptysis
• Chest pain, dyspnea
• Unresolving pneumonia despite antibiotics
• Rapid clinical deterioration in neutropenic or critically ill patients

Laboratory and Diagnostic Tests:

Test	Utility
KOH Mount	Rapid screening (e.g., septate hyphae or yeast)
LPCB/Calcofluor white stain	Detailed fungal morphology
Culture (SDA, Mycosel)	Identification of fungal pathogen
CrAg (serum/CSF)	Cryptococcal antigen detection
Galactomannan assay	Invasive aspergillosis
β-D-glucan test	General fungal infection marker
BAL or lung biopsy	Definitive diagnosis in deep infections
CT Chest	Halo sign, air crescent (esp. in Aspergillus)

Treatment (based on pathogen)

Fungus	Drug of Choice
Aspergillus	Voriconazole / Isavuconazole
Cryptococcus	Amphotericin B + Flucytosine (induction), then Fluconazole
Pneumocystis jirovecii	Cotrimoxazole (TMP-SMX)
Mucormycosis	Liposomal Amphotericin B
Histoplasma / Blastomyces	Itraconazole / Amphotericin B (severe)

Prevention

• HEPA filters in oncology wards
• Prophylactic antifungals (e.g., posaconazole) in neutropenic patients
• Early screening in symptomatic cancer patients

Keynotes on Fungal Pneumonia

1. Fungal pneumonia primarily affects immunocompromised patients, such as those with cancer, HIV, or post-transplant status.
2. Although rare in healthy hosts, fungal pneumonia becomes life-threatening in neutropenic or severely immunosuppressed individuals.
3. Common pathogens include Aspergillus spp., Cryptococcus neoformans, Pneumocystis jirovecii, and Mucorales species.
4. Patients often present with fever, non-resolving cough, hemoptysis, and chest pain despite broad-spectrum antibiotic therapy.
5. Radiological signs like the halo sign or air crescent on CT suggest invasive aspergillosis.
6. KOH mount and calcofluor white stain rapidly detect fungal hyphae or yeast cells in clinical specimens.
7. Fungal cultures on SDA or Mycosel media help confirm species, although they require time and expertise.
8. Cryptococcus appears as an encapsulated yeast with a halo, best visualized using India Ink preparation.
9. Pneumocystis jirovecii causes bilateral ground-glass opacities and foamy alveolar exudates, especially in HIV/AIDS.
10. Galactomannan and β-D-glucan assays assist in the early diagnosis of invasive fungal infections.
11. Serum or CSF cryptococcal antigen (CrAg) test detects Cryptococcus with high sensitivity and specificity.
12. Liposomal amphotericin B, voriconazole, fluconazole, and cotrimoxazole remain the mainstays of treatment.
13. Prompt initiation of antifungals significantly improves prognosis and reduces mortality in invasive fungal pneumonia.
14. Delayed diagnosis often results in disseminated disease, CNS involvement, or multi-organ failure.
15. Risk factors include corticosteroids, prolonged neutropenia, broad-spectrum antibiotic use, and ICU stays.
16. Air filtration with HEPA and antifungal prophylaxis helps prevent infection in high-risk hospital units.
17. BAL or lung biopsy remains the gold standard for diagnosis when imaging and sputum tests are inconclusive.
18. Mucormycosis requires urgent surgical debridement along with high-dose amphotericin B therapy.
19. Mixed infections with bacteria or other fungi complicate diagnosis and treatment in oncology patients.
20. Clinicians must maintain a high suspicion for fungal pneumonia when antibiotics fail to resolve lung infiltrates.

Further Readings

• https://www.verywellhealth.com/fungal-pneumonia-5179190
• https://my.clevelandclinic.org/health/diseases/4471-pneumonia
• https://journal.chestnet.org/article/S0012-3692(23)05558-7/abstract
• https://publications.ersnet.org/content/erj/64/5/2400803
• https://pmc.ncbi.nlm.nih.gov/articles/PMC9106206/
• https://radiopaedia.org/articles/pulmonary-fungal-disease
• https://journals.lww.com/ascp/fulltext/2015/03020/fungal_pneumonia_in_intensive_care_unit__when_to.4.aspx
• https://www.sciencedirect.com/topics/medicine-and-dentistry/fungal-pneumonia
• https://www.thoracic.org/statements/resources/tb-opi/treatment-of-fungal-infections-in-adult-pulmonary-critical-care-and-sleep-medicine.pdf